# Current clinical practice in antibiotic treatment of Staphylococcus aureus bacteraemia: results from a survey in five European countries

D T P Buis, J M Prins, L Betica-Radic, M G J de Boer, M Ekkelenkamp, D Kofteridis, N Peiffer-Smadja, J Schouten, N Spernovasilis, P Tattevin, et al.

<figure><img src="image_1.png" /></figure>

## To cite this version:

D T P Buis, J M Prins, L Betica-Radic, M G J de Boer, M Ekkelenkamp, et al. Current clinical practice in antibiotic treatment of Staphylococcus aureus bacteraemia: results from a survey in five European countries. Journal of Antimicrobial Chemotherapy, 2022, 77 (10), pp.2827-2834. 10.1093/jac/dkac237. hal-03777270

HAL Id: hal-03777270

https://hal.science/hal-03777270

Submitted on 19 Feb 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

<figure><img src="image_2.png" /></figure>
# Current clinical practice in antibiotic treatment of Staphylococcus aureus bacteraemia: results from a survey in five European countries

D T P Buis, J M Prins, L Betica-Radic, M G J de Boer, M Ekkelenkamp, D Kofteridis, N Peiffer-Smadja, J Schouten, N Spernovasilis, P Tattevin, et al.

<figure><img src="image_1.png" /></figure>

## To cite this version:

D T P Buis, J M Prins, L Betica-Radic, M G J de Boer, M Ekkelenkamp, et al. Current clinical practice in antibiotic treatment of Staphylococcus aureus bacteraemia: results from a survey in five European countries. Journal of Antimicrobial Chemotherapy, 2022, 77 (10), pp.2827-2834. 10.1093/jac/dkac237. hal-03777270

HAL Id: hal-03777270

https://hal.science/hal-03777270v1

Submitted on 19 Feb 2024

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_2.png" /></figure>
# Current clinical practice in antibiotic treatment of *Staphylococcus aureus* bacteraemia: results from a survey in five European countries

D. T. P. Buis<fnref n="1" />*, J. M. Prins<fnref n="1" />, L. Betica-Radic², M. G. J. de Boer³, M. Ekkelenkamp⁴, D. Kofteridis<fnref n="5" />, N. Peiffer-Smadja⁶, J. Schouten⁷, N. Spernovasilis<fnref n="5" />,⁸, P. Tattevin ID <fnref n="9" />, J. ten Oever ID ¹⁰ and K. C. E. Sigaloff<fnref n="1" /> on behalf of the ESCMID Study Group for Antimicrobial Stewardship (ESGAP)

Received 28 March 2022; accepted 17 June 2022

**Objectives:** To determine clinical practice variation and identify knowledge gaps in antibiotic treatment of *Staphylococcus aureus* bacteraemia (SAB).

**Methods:** A web-based survey with questions addressing antibiotic treatment of SAB was distributed through the ESGAP network among infectious disease specialists, clinical microbiologists and internists in Croatia, France, Greece, the Netherlands and the UK between July 2021 and November 2021.

**Results:** A total number of 1687 respondents opened the survey link, of whom 677 (40%) answered at least one question. For MSSA and MRSA bacteraemia, 98% and 94% preferred initial monotherapy, respectively. In patients with SAB and non-removable infected prosthetic material, between 80% and 90% would use rifampicin as part of the treatment. For bone and joint infections, 65%–77% of respondents would consider oral step-down therapy, but for endovascular infections only 12%–32% would. Respondents recommended widely varying treatment durations for SAB with different foci of infection. Overall, 48% stated they used ¹⁸F-fluorodeoxyglucose positron emission tomography/CT (18F-FDG-PET/CT) to guide antibiotic treatment duration. Persistent bacteraemia was the only risk factor for complicated SAB that would prompt a majority to extend treatment from 2 to 4–6 weeks.

**Conclusions:** This survey in five European countries shows considerable clinical practice variation between and within countries in the antibiotic management of SAB, in particular regarding oral step-down therapy, choice of oral antibiotic agents, treatment duration and use of 18F-FDG-PET/CT. Physicians use varying criteria for treatment decisions, as evidence from clinical trials is often lacking. These areas of practice variation could be used to prioritize future studies for further improvement of SAB care.

## Introduction

*Staphylococcus aureus* bacteraemia (SAB) is an exceptionally heterogeneous disease and its clinical course can range from mild to life-threatening.<fnref n="1" /> This clinical heterogeneity is the result of complex interplay between pathogen and host factors, and

is reflected by varying distributions of clinical phenotypes and mortality rates between observational cohort studies.<fnref n="1" />,²

In recent decades, evidence-based interventions including infectious disease (ID) consultation, follow-up blood cultures, echocardiography and source control interventions have improved clinical outcomes in SAB patients.³⁻<fnref n="5" /> Conversely,

<footnote n="1">¹Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Internal Medicine, Division of Infectious Diseases, Amsterdam Institute for Infection and Immunity, De Boelelaan 1117, Amsterdam, The Netherlands; ²General Hospital Dubrovnik, Department of Infectious Diseases, University of Dubrovnik, Dubrovnik, Croatia; ³Leiden University Medical Center, Department of Infectious Diseases, Leiden, The Netherlands; ⁴UMC Utrecht, Department of Medical Microbiology, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands;</footnote>

<footnote n="5">⁵Department of Internal Medicine & Infectious Diseases, University Hospital of Heraklion, Heraklion, Greece; ⁶Infectious Disease Department, Bichat-Claude Bernard Hospital, Assistance-Publique Hôpitaux de Paris, Paris, France; ⁷Department of Intensive Care Medicine, Radboudumc, Nijmegen, The Netherlands; ⁸Department of Infectious Diseases, German Oncology Center, Limassol, Cyprus;</footnote>

<footnote n="9">⁹Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France; ¹⁰Radboud University Medical Center, Department of Internal Medicine and Radboud Center for Infectious Diseases, Geert Grooteplein Zuid 10, Nijmegen, The Netherlands</footnote>

<footnote>*Corresponding author. E-mail: d.t.p.buis@amsterdamumc.nl</footnote>
# Current clinical practice in antibiotic treatment of *Staphylococcus aureus* bacteraemia: results from a survey in five European countries

D. T. P. Buis<fnref n="1" />*, J. M. Prins<fnref n="1" />, L. Betica-Radic², M. G. J. de Boer³, M. Ekkelenkamp⁴, D. Kofteridis<fnref n="5" />, N. Peiffer-Smadja⁶, J. Schouten⁷, N. Spernovasilis<fnref n="5" />,⁸, P. Tattevin ID <fnref n="9" />, J. ten Oever ID ¹⁰ and K. C. E. Sigaloff<fnref n="1" /> on behalf of the ESCMID Study Group for Antimicrobial Stewardship (ESGAP)

Received 28 March 2022; accepted 17 June 2022

**Objectives:** To determine clinical practice variation and identify knowledge gaps in antibiotic treatment of *Staphylococcus aureus* bacteraemia (SAB).

**Methods:** A web-based survey with questions addressing antibiotic treatment of SAB was distributed through the ESGAP network among infectious disease specialists, clinical microbiologists and internists in Croatia, France, Greece, the Netherlands and the UK between July 2021 and November 2021.

**Results:** A total number of 1687 respondents opened the survey link, of whom 677 (40%) answered at least one question. For MSSA and MRSA bacteraemia, 98% and 94% preferred initial monotherapy, respectively. In patients with SAB and non-removable infected prosthetic material, between 80% and 90% would use rifampicin as part of the treatment. For bone and joint infections, 65%–77% of respondents would consider oral step-down therapy, but for endovascular infections only 12%–32% would. Respondents recommended widely varying treatment durations for SAB with different foci of infection. Overall, 48% stated they used ¹⁸F-fluorodeoxyglucose positron emission tomography/CT (18F-FDG-PET/CT) to guide antibiotic treatment duration. Persistent bacteraemia was the only risk factor for complicated SAB that would prompt a majority to extend treatment from 2 to 4–6 weeks.

**Conclusions:** This survey in five European countries shows considerable clinical practice variation between and within countries in the antibiotic management of SAB, in particular regarding oral step-down therapy, choice of oral antibiotic agents, treatment duration and use of 18F-FDG-PET/CT. Physicians use varying criteria for treatment decisions, as evidence from clinical trials is often lacking. These areas of practice variation could be used to prioritize future studies for further improvement of SAB care.

## Introduction

*Staphylococcus aureus* bacteraemia (SAB) is an exceptionally heterogeneous disease and its clinical course can range from mild to life-threatening.<fnref n="1" /> This clinical heterogeneity is the result of complex interplay between pathogen and host factors, and

is reflected by varying distributions of clinical phenotypes and mortality rates between observational cohort studies.<fnref n="1" />,²

In recent decades, evidence-based interventions including infectious disease (ID) consultation, follow-up blood cultures, echocardiography and source control interventions have improved clinical outcomes in SAB patients.³⁻<fnref n="5" /> Conversely,

<footnote n="1">¹Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Internal Medicine, Division of Infectious Diseases, Amsterdam Institute for Infection and Immunity, De Boelelaan 1117, Amsterdam, The Netherlands; ²General Hospital Dubrovnik, Department of Infectious Diseases, University of Dubrovnik, Dubrovnik, Croatia; ³Leiden University Medical Center, Department of Infectious Diseases, Leiden, The Netherlands; ⁴UMC Utrecht, Department of Medical Microbiology, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands;</footnote>

<footnote n="5">⁵Department of Internal Medicine & Infectious Diseases, University Hospital of Heraklion, Heraklion, Greece; ⁶Infectious Disease Department, Bichat-Claude Bernard Hospital, Assistance-Publique Hôpitaux de Paris, Paris, France; ⁷Department of Intensive Care Medicine, Radboudumc, Nijmegen, The Netherlands; ⁸Department of Infectious Diseases, German Oncology Center, Limassol, Cyprus;</footnote>

<footnote n="9">⁹Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France; ¹⁰Radboud University Medical Center, Department of Internal Medicine and Radboud Center for Infectious Diseases, Geert Grooteplein Zuid 10, Nijmegen, The Netherlands</footnote>

<footnote>*Corresponding author. E-mail: d.t.p.buis@amsterdamumc.nl</footnote>
appropriate antibiotic treatment, one of the key components of SAB management, is still guided by evidence of poor quality.¹ This is reflected in current guidelines on SAB, which vary widely in their recommendations regarding choice of antibiotic agents, treatment duration and optimal administration route.⁶⁻⁹

It is likely that the paucity of high-level evidence results in clinical practice variation in antibiotic treatment of SAB. In order to substantiate the clinical practice variation, a web-based survey was designed and distributed among ID specialists, clinical microbiologists and internists in five European countries. Areas of variation in management may indicate knowledge gaps, and identifying them may therefore guide future research efforts.

## Methods

### Survey development

We designed a web-based survey in two subsequent steps. First, we organized an online discussion with ID specialists and clinical microbiologists involved in SAB management to identify topics for inclusion in the survey. We developed a first draft of the survey with questions based on these topics. Second, this draft was tested in an independent group of ID specialists and clinical microbiologists. Their comments were used to adjust the survey and develop a final version (Appendix A, available as Supplementary data at JAC Online). The final version included 17 questions addressing the following topics: choice of antibiotic agents; use of rifampicin; oral antibiotic step-down therapy; and treatment duration. We also included two scenarios describing patients with SAB, with questions on recommended antibiotic treatment duration to illustrate clinical practice.

### Survey distribution

Target respondents included ID specialists, clinical microbiologists, internists and residents in training for one of these specialties. Five European countries were invited through the ESCMID Study Group for Antimicrobial Stewardship (ESGAP) to participate in the survey: the Netherlands, France, the UK, Greece and Croatia. These countries were chosen based on their geographical spread in Europe. We did not perform a formal sample size calculation, but aimed for at least 50 respondents per country. Distribution of the survey was initiated on 6 July 2021 and data collection was stopped on 30 November 2021. There were no financial or other incentives provided to the target respondents.

In all countries, the survey was shared by a web link and respondents were invited to forward the survey link to their colleagues. In the Netherlands, the survey was distributed through the Dutch Working Party on Antibiotic Policy, the Dutch Society for Infectious Disease specialists and the Dutch Society for Medical Microbiology. In France, the survey was shared via the French Society for Infectious Diseases, the French National Society for Internal Medicine, the French Young Infectious Diseases Network and the Young Internal Medicine Specialists Network. The survey was distributed in Croatia through the Croatian Society of Infectious Disease and the Croatian Society of Clinical Microbiology. In Greece, the survey was distributed through a network of ID specialists within the Greek Society for Infectious Diseases. In the UK, the survey was shared through the British Infection Association.

### Data analysis

A descriptive analysis of all survey questions was performed. Both complete and partially completed surveys were included in the data analysis.

Continuous and categorical variables were presented as median (IQR) and absolute number (percentage), respectively. A sensitivity analysis was performed, excluding consultants in training. All analyses were performed using R version 4.0.3.

## Results

### Characteristics of respondents

The survey link was opened 1687 times. A total of 677 (40%) respondents answered at least one question concerning antibiotic treatment of SAB. Table 1 describes the demographic characteristics of these 677 respondents. Overall, 78% (527/677) of respondents completed the survey. Participants practised in France (45%), the Netherlands (18%), Greece (14%), the UK (13%), Croatia (5%) or another country (4%). Most respondents were ID specialists (56%), clinical microbiologists (21%) or internists (19%). Overall, 78% of respondents were registered consultants, while 22% were still in training. The majority of consultants had been registered for 0–10 years. Most respondents (65%) indicated they were involved in clinical decision-making in 11–50 cases of SAB per year and 18% were involved in more than 50 cases of SAB each year.

### Antibiotic agents for MSSA bacteraemia

For initial treatment of monobacterial MSSA bacteraemia, 98% (664/677) favoured antibiotic monotherapy and 2% (13/677) combination therapy. Of those who preferred antibiotic monotherapy, 81% (536/664) indicated an anti-staphylococcal

<table><caption>**Table 1.** Characteristics of survey respondents who answered at least one survey question (n=677)</caption><thead><tr><th>Characteristic</th><th>n (%)</th></tr></thead><tbody><tr><td>Country</td><td></td></tr><tr><td>France</td><td>306 (45)</td></tr><tr><td>The Netherlands</td><td>124 (18)</td></tr><tr><td>Greece</td><td>98 (14)</td></tr><tr><td>UK</td><td>86 (13)</td></tr><tr><td>Croatia</td><td>37 (5)</td></tr><tr><td>Other</td><td>26 (4)</td></tr><tr><td>Medical specialty</td><td></td></tr><tr><td>ID</td><td>380 (56)</td></tr><tr><td>Clinical microbiology</td><td>143 (21)</td></tr><tr><td>Internal medicine</td><td>132 (19)</td></tr><tr><td>Other</td><td>22 (3)</td></tr><tr><td>Years registered as consultant</td><td></td></tr><tr><td>In training for consultant</td><td>148 (22)</td></tr><tr><td>0–10</td><td>317 (47)</td></tr><tr><td>11–20</td><td>126 (19)</td></tr><tr><td>21–30</td><td>56 (8)</td></tr><tr><td>>30</td><td>30 (4)</td></tr><tr><td>Number of SAB cases respondent is involved in per year</td><td></td></tr><tr><td>0–10</td><td>117 (17)</td></tr><tr><td>11–20</td><td>190 (28)</td></tr><tr><td>21–50</td><td>250 (37)</td></tr><tr><td>>50</td><td>120 (18)</td></tr></tbody></table>
appropriate antibiotic treatment, one of the key components of SAB management, is still guided by evidence of poor quality.¹ This is reflected in current guidelines on SAB, which vary widely in their recommendations regarding choice of antibiotic agents, treatment duration and optimal administration route.⁶⁻⁹

It is likely that the paucity of high-level evidence results in clinical practice variation in antibiotic treatment of SAB. In order to substantiate the clinical practice variation, a web-based survey was designed and distributed among ID specialists, clinical microbiologists and internists in five European countries. Areas of variation in management may indicate knowledge gaps, and identifying them may therefore guide future research efforts.

## Methods

### Survey development

We designed a web-based survey in two subsequent steps. First, we organized an online discussion with ID specialists and clinical microbiologists involved in SAB management to identify topics for inclusion in the survey. We developed a first draft of the survey with questions based on these topics. Second, this draft was tested in an independent group of ID specialists and clinical microbiologists. Their comments were used to adjust the survey and develop a final version (Appendix A, available as Supplementary data at JAC Online). The final version included 17 questions addressing the following topics: choice of antibiotic agents; use of rifampicin; oral antibiotic step-down therapy; and treatment duration. We also included two scenarios describing patients with SAB, with questions on recommended antibiotic treatment duration to illustrate clinical practice.

### Survey distribution

Target respondents included ID specialists, clinical microbiologists, internists and residents in training for one of these specialties. Five European countries were invited through the ESCMID Study Group for Antimicrobial Stewardship (ESGAP) to participate in the survey: the Netherlands, France, the UK, Greece and Croatia. These countries were chosen based on their geographical spread in Europe. We did not perform a formal sample size calculation, but aimed for at least 50 respondents per country. Distribution of the survey was initiated on 6 July 2021 and data collection was stopped on 30 November 2021. There were no financial or other incentives provided to the target respondents.

In all countries, the survey was shared by a web link and respondents were invited to forward the survey link to their colleagues. In the Netherlands, the survey was distributed through the Dutch Working Party on Antibiotic Policy, the Dutch Society for Infectious Disease specialists and the Dutch Society for Medical Microbiology. In France, the survey was shared via the French Society for Infectious Diseases, the French National Society for Internal Medicine, the French Young Infectious Diseases Network and the Young Internal Medicine Specialists Network. The survey was distributed in Croatia through the Croatian Society of Infectious Disease and the Croatian Society of Clinical Microbiology. In Greece, the survey was distributed through a network of ID specialists within the Greek Society for Infectious Diseases. In the UK, the survey was shared through the British Infection Association.

### Data analysis

A descriptive analysis of all survey questions was performed. Both complete and partially completed surveys were included in the data analysis.

Continuous and categorical variables were presented as median (IQR) and absolute number (percentage), respectively. A sensitivity analysis was performed, excluding consultants in training. All analyses were performed using R version 4.0.3.

## Results

### Characteristics of respondents

The survey link was opened 1687 times. A total of 677 (40%) respondents answered at least one question concerning antibiotic treatment of SAB. Table 1 describes the demographic characteristics of these 677 respondents. Overall, 78% (527/677) of respondents completed the survey. Participants practised in France (45%), the Netherlands (18%), Greece (14%), the UK (13%), Croatia (5%) or another country (4%). Most respondents were ID specialists (56%), clinical microbiologists (21%) or internists (19%). Overall, 78% of respondents were registered consultants, while 22% were still in training. The majority of consultants had been registered for 0–10 years. Most respondents (65%) indicated they were involved in clinical decision-making in 11–50 cases of SAB per year and 18% were involved in more than 50 cases of SAB each year.

### Antibiotic agents for MSSA bacteraemia

For initial treatment of monobacterial MSSA bacteraemia, 98% (664/677) favoured antibiotic monotherapy and 2% (13/677) combination therapy. Of those who preferred antibiotic monotherapy, 81% (536/664) indicated an anti-staphylococcal

<table><caption>**Table 1.** Characteristics of survey respondents who answered at least one survey question (n=677)</caption><thead><tr><th>Characteristic</th><th>n (%)</th></tr></thead><tbody><tr><td>Country</td><td></td></tr><tr><td>France</td><td>306 (45)</td></tr><tr><td>The Netherlands</td><td>124 (18)</td></tr><tr><td>Greece</td><td>98 (14)</td></tr><tr><td>UK</td><td>86 (13)</td></tr><tr><td>Croatia</td><td>37 (5)</td></tr><tr><td>Other</td><td>26 (4)</td></tr><tr><td>Medical specialty</td><td></td></tr><tr><td>ID</td><td>380 (56)</td></tr><tr><td>Clinical microbiology</td><td>143 (21)</td></tr><tr><td>Internal medicine</td><td>132 (19)</td></tr><tr><td>Other</td><td>22 (3)</td></tr><tr><td>Years registered as consultant</td><td></td></tr><tr><td>In training for consultant</td><td>148 (22)</td></tr><tr><td>0–10</td><td>317 (47)</td></tr><tr><td>11–20</td><td>126 (19)</td></tr><tr><td>21–30</td><td>56 (8)</td></tr><tr><td>>30</td><td>30 (4)</td></tr><tr><td>Number of SAB cases respondent is involved in per year</td><td></td></tr><tr><td>0–10</td><td>117 (17)</td></tr><tr><td>11–20</td><td>190 (28)</td></tr><tr><td>21–50</td><td>250 (37)</td></tr><tr><td>>50</td><td>120 (18)</td></tr></tbody></table>
penicillin as their first-choice antibiotic agent and 16% (108/664) a first-generation cephalosporin (Figure S1). When treating a patient with MSSA bacteraemia without CNS infection, 74% (496/668) would consider first-generation cephalosporins to have equivalent clinical effectiveness as anti-staphylococcal penicillins. This percentage varied between 39% (33/84) and 91% (112/123) in the different countries (Table S1).

## Antibiotic agents for MRSA bacteraemia

When treating a patient with confirmed monobacterial MRSA bacteraemia, 94% (635/677) would prefer initial antibiotic monotherapy. Of these respondents, 71% (452/635) preferred a glycopeptide (e.g. vancomycin) as initial antibiotic therapy and 23% (148/635) a lipopeptide (e.g. daptomycin) (Figure S2). Respondents using combination therapy recommended widely varying regimens. In this group, the combination of a glycopeptide plus an aminoglycoside was the most used regimen (7/42; 17%).

## Use of rifampicin

In patients with SAB and non-removable infected prosthetic material, between 80% (448/560) and 90% (503/560) of respondents would use rifampicin as part of the treatment, provided the isolates were susceptible (Figure S3). For SAB and an associated infected joint prosthesis, 90% (503/560) would treat with a rifampicin-based therapy.

## Oral step-down therapy

Figure 1 shows the percentage of respondents who would consider oral step-down antibiotic therapy per infectious focus. Only 12% (68/560) would not consider oral step-down antibiotic therapy in any of the infectious foci surveyed. For bone and joint infections, 65%-77% of respondents, and for skin-and-soft-tissue infections 82% (458/560) of respondents, would consider using oral step-down therapy. In patients with endovascular infections, including central vascular catheter infection and native and prosthetic valve endocarditis, 32% (177/560), 24% (136/560) and 12% (67/560) of respondents, respectively, would consider oral step-down antibiotics.

Most respondents considered clearance of bacteraemia 48-72 h after initiation of adequate antibiotic treatment (370/490; 76%) and absence of CNS infection (336/490; 69%) as requirements for oral step-down therapy, provided the patient is able to take oral medication (Figure S4). Transoesophageal echocardiography (TEE) without signs of endocarditis was more frequently reported as a requirement than normal transthoracic echocardiography (TTE) (252/490; 51% versus 197/490; 40%). Only a minority (116/490; 24%) would use initiation of adequate antibiotic therapy within 48 h after blood culture collection and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT (18F-FDG-PET/CT) without signs of endocarditis or metastatic infections (120/490; 24%) as a requirement for using oral step-down therapy.

<figure><img src="image_3.png" /><figcaption>**Figure 1.** Foci of infection for which participants would consider oral step-down antibiotic therapy (n = 560). SSTI, skin-and-soft-tissue infection; UTI, urinary tract infection; n, the number of respondents who chose a specific answer option. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.</figcaption></figure>
penicillin as their first-choice antibiotic agent and 16% (108/664) a first-generation cephalosporin (Figure S1). When treating a patient with MSSA bacteraemia without CNS infection, 74% (496/668) would consider first-generation cephalosporins to have equivalent clinical effectiveness as anti-staphylococcal penicillins. This percentage varied between 39% (33/84) and 91% (112/123) in the different countries (Table S1).

## Antibiotic agents for MRSA bacteraemia

When treating a patient with confirmed monobacterial MRSA bacteraemia, 94% (635/677) would prefer initial antibiotic monotherapy. Of these respondents, 71% (452/635) preferred a glycopeptide (e.g. vancomycin) as initial antibiotic therapy and 23% (148/635) a lipopeptide (e.g. daptomycin) (Figure S2). Respondents using combination therapy recommended widely varying regimens. In this group, the combination of a glycopeptide plus an aminoglycoside was the most used regimen (7/42; 17%).

## Use of rifampicin

In patients with SAB and non-removable infected prosthetic material, between 80% (448/560) and 90% (503/560) of respondents would use rifampicin as part of the treatment, provided the isolates were susceptible (Figure S3). For SAB and an associated infected joint prosthesis, 90% (503/560) would treat with a rifampicin-based therapy.

## Oral step-down therapy

Figure 1 shows the percentage of respondents who would consider oral step-down antibiotic therapy per infectious focus. Only 12% (68/560) would not consider oral step-down antibiotic therapy in any of the infectious foci surveyed. For bone and joint infections, 65%-77% of respondents, and for skin-and-soft-tissue infections 82% (458/560) of respondents, would consider using oral step-down therapy. In patients with endovascular infections, including central vascular catheter infection and native and prosthetic valve endocarditis, 32% (177/560), 24% (136/560) and 12% (67/560) of respondents, respectively, would consider oral step-down antibiotics.

Most respondents considered clearance of bacteraemia 48-72 h after initiation of adequate antibiotic treatment (370/490; 76%) and absence of CNS infection (336/490; 69%) as requirements for oral step-down therapy, provided the patient is able to take oral medication (Figure S4). Transoesophageal echocardiography (TEE) without signs of endocarditis was more frequently reported as a requirement than normal transthoracic echocardiography (TTE) (252/490; 51% versus 197/490; 40%). Only a minority (116/490; 24%) would use initiation of adequate antibiotic therapy within 48 h after blood culture collection and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT (18F-FDG-PET/CT) without signs of endocarditis or metastatic infections (120/490; 24%) as a requirement for using oral step-down therapy.

<figure><img src="image_3.png" /><figcaption>**Figure 1.** Foci of infection for which participants would consider oral step-down antibiotic therapy (n = 560). SSTI, skin-and-soft-tissue infection; UTI, urinary tract infection; n, the number of respondents who chose a specific answer option. This figure appears in colour in the online version of JAC and in black and white in the print version of JAC.</figcaption></figure>
## Antibiotic agents for oral step-down therapy

When treating a patient with MSSA bacteraemia with oral step-down therapy, 65% (319/489) preferred monotherapy and 35% (170/489) combination therapy, assuming there is no implanted prosthetic material and the isolate is susceptible to the drug. Preferred agents for oral step-down were anti-staphylococcal penicillins and clindamycin (both 32%). Eleven percent (36/319) of respondents most commonly prescribed a fluoroquinolone and 10% (33/319) trimethoprim/sulfamethoxazole (Figure S5). For oral-step down therapy in a patient with MRSA bacteraemia, 68% (330/486) would recommend monotherapy over combination therapy. Linezolid (114/330; 35%), clindamycin (107/330; 32%) and trimethoprim/sulfamethoxazole (65/330; 20%) were most commonly prescribed as monotherapy (Figure S6). A fluoroquinolone plus rifampicin was the most used oral step-down combination regimen in both MSSA (39/170; 23%) and MRSA (39/156; 25%) bacteraemia.

## Antibiotic treatment duration

Table 2 shows respondents' preferences concerning antibiotic treatment duration in patients with SAB without implanted prosthetic material. For arthritis, 17% (91/536) favoured 2 weeks, 48% (259/536) 4 weeks and 34% (182/536) 6 weeks of antibiotic treatment. When managing a patient with native valve endocarditis, 59% (317/536) indicated they would prefer 6 weeks of treatment and 37% (198/536) chose 4 weeks of treatment. The majority of respondents (448/536; 84%) would treat a patient with pneumonia without abscess for 2 weeks.

Approximately half of respondents (255/536; 48%) stated they used 18F-FDG-PET/CT to guide antibiotic treatment duration in SAB. Respondents from Greece reported the lowest use of 18F-FDG-PET/CT (13/83; 16%) and respondents from the Netherlands the highest (97/106; 90%) (Table S2). Respondents were further asked to indicate which factors would make them consider extending antibiotic therapy from 2 to 4–6 weeks, assuming TEE did not show signs of endocarditis and, if they used it, 18F-FDG-PET/CT did not show signs of metastatic infection. Figure S7 displays the results for respondents using 18F-FDG-PET/CT and not using 18F-FDG-PET/CT separately. In both groups, a large majority [215/255, (84%) and 224/281 (80%), respectively] stated that persistent bacteraemia after 72 h of adequate treatment was a reason to extend treatment. For all other factors, only a minority of respondents stated it would make them consider extending antibiotic therapy.

Respondents using 18F-FDG-PET/CT more frequently reported community acquisition of infection as a reason to extend treatment than respondents not using 18F-FDG-PET/CT [56/255 (22%) versus 34/281 (12%)].

## Scenarios

Respondents were asked to provide a recommendation on duration of antibiotic treatment in two scenarios describing patients with SAB. A full description of both scenarios is provided in Figure 2. Overall, 527 respondents provided their recommended treatment durations. For scenario 1, recommended duration was 2 weeks for 89% (467/527) of respondents and 4 weeks for 8% (40/527) of respondents. For scenario 2, recommended durations of therapy were 2 weeks for 55% (292/527), 4 weeks for 23% (119/527) and 6 weeks for 18% (97/527) of respondents.

## Sensitivity analysis

No substantial differences were observed between the results of all respondents and those of registered consultants only, excluding those in training (data not shown).

## Discussion

This survey in five European countries showed considerable clinical practice variation between and within countries in the anti-biotic management of SAB. Areas of consensus were choice of IV antibiotic agents, use of combination therapy and use of rifampicin-based treatment in prosthetic material infection. Main areas of controversy were eligibility for oral step-down therapy, choice of oral antibiotic agents, treatment duration and use of 18F-FDG-PET/CT.

## Antibiotic treatment of MSSA bacteraemia

A large majority of respondents preferred monotherapy for treatment of microbiologically confirmed MSSA and MRSA bacteraemia. Most respondents would use an anti-staphylococcal penicillin for MSSA bacteraemia. On the other hand, three-quarters of respondents considered first-generation cephalosporins to have equivalent clinical effectiveness to anti-staphylococcal penicillins in MSSA bacteraemia without CNS infection. This is considerably higher than in a previous study among ID specialists in the USA and Canada, of whom only 32% considered nafcillin and cefazolin equivalent in the treatment of left-sided MSSA endocarditis without CNS involvement.¹⁰ This difference might be explained by the recent publication of observational studies indicating

<table><caption>**Table 2.** Preferred antibiotic treatment duration in SAB patients without implanted prosthetic material (n=536)</caption><thead><tr><th>Antibiotic treatment duration (weeks)</th><th>Arthritis n (%)</th><th>Native valve endocarditis n (%)</th><th>Osteomyelitis n (%)</th><th>Pneumonia without abscess n (%)</th><th>Septic thrombophlebitis n (%)</th><th>Vertebral osteomyelitis without abscess n (%)</th></tr></thead><tbody><tr><td>2</td><td>91 (17)</td><td>6 (1)</td><td>7 (1)</td><td>448 (84)</td><td>188 (35)</td><td>8 (1)</td></tr><tr><td>4</td><td>259 (48)</td><td>198 (37)</td><td>64 (12)</td><td>63 (12)</td><td>236 (44)</td><td>52 (10)</td></tr><tr><td>6</td><td>182 (34)</td><td>317 (59)</td><td>407 (76)</td><td>24 (4)</td><td>105 (20)</td><td>423 (79)</td></tr><tr><td>&gt;6</td><td>4 (1)</td><td>15 (3)</td><td>58 (11)</td><td>1 (0)</td><td>7 (1)</td><td>53 (10)</td></tr></tbody></table>
## Antibiotic agents for oral step-down therapy

When treating a patient with MSSA bacteraemia with oral step-down therapy, 65% (319/489) preferred monotherapy and 35% (170/489) combination therapy, assuming there is no implanted prosthetic material and the isolate is susceptible to the drug. Preferred agents for oral step-down were anti-staphylococcal penicillins and clindamycin (both 32%). Eleven percent (36/319) of respondents most commonly prescribed a fluoroquinolone and 10% (33/319) trimethoprim/sulfamethoxazole (Figure S5). For oral-step down therapy in a patient with MRSA bacteraemia, 68% (330/486) would recommend monotherapy over combination therapy. Linezolid (114/330; 35%), clindamycin (107/330; 32%) and trimethoprim/sulfamethoxazole (65/330; 20%) were most commonly prescribed as monotherapy (Figure S6). A fluoroquinolone plus rifampicin was the most used oral step-down combination regimen in both MSSA (39/170; 23%) and MRSA (39/156; 25%) bacteraemia.

## Antibiotic treatment duration

Table 2 shows respondents' preferences concerning antibiotic treatment duration in patients with SAB without implanted prosthetic material. For arthritis, 17% (91/536) favoured 2 weeks, 48% (259/536) 4 weeks and 34% (182/536) 6 weeks of antibiotic treatment. When managing a patient with native valve endocarditis, 59% (317/536) indicated they would prefer 6 weeks of treatment and 37% (198/536) chose 4 weeks of treatment. The majority of respondents (448/536; 84%) would treat a patient with pneumonia without abscess for 2 weeks.

Approximately half of respondents (255/536; 48%) stated they used 18F-FDG-PET/CT to guide antibiotic treatment duration in SAB. Respondents from Greece reported the lowest use of 18F-FDG-PET/CT (13/83; 16%) and respondents from the Netherlands the highest (97/106; 90%) (Table S2). Respondents were further asked to indicate which factors would make them consider extending antibiotic therapy from 2 to 4–6 weeks, assuming TEE did not show signs of endocarditis and, if they used it, 18F-FDG-PET/CT did not show signs of metastatic infection. Figure S7 displays the results for respondents using 18F-FDG-PET/CT and not using 18F-FDG-PET/CT separately. In both groups, a large majority [215/255, (84%) and 224/281 (80%), respectively] stated that persistent bacteraemia after 72 h of adequate treatment was a reason to extend treatment. For all other factors, only a minority of respondents stated it would make them consider extending antibiotic therapy.

Respondents using 18F-FDG-PET/CT more frequently reported community acquisition of infection as a reason to extend treatment than respondents not using 18F-FDG-PET/CT [56/255 (22%) versus 34/281 (12%)].

## Scenarios

Respondents were asked to provide a recommendation on duration of antibiotic treatment in two scenarios describing patients with SAB. A full description of both scenarios is provided in Figure 2. Overall, 527 respondents provided their recommendations on treatment durations. For scenario 1, recommended duration was 2 weeks for 89% (467/527) of respondents and 4 weeks for 8% (40/527) of respondents. For scenario 2, recommended durations of therapy were 2 weeks for 55% (292/527), 4 weeks for 23% (119/527) and 6 weeks for 18% (97/527) of respondents.

## Sensitivity analysis

No substantial differences were observed between the results of all respondents and those of registered consultants only, excluding those in training (data not shown).

## Discussion

This survey in five European countries showed considerable clinical practice variation between and within countries in the antibiotic management of SAB. Areas of consensus were choice of IV antibiotic agents, use of combination therapy and use of rifampicin-based treatment in prosthetic material infection. Main areas of controversy were eligibility for oral step-down therapy, choice of oral antibiotic agents, treatment duration and use of 18F-FDG-PET/CT.

## Antibiotic treatment of MSSA bacteraemia

A large majority of respondents preferred monotherapy for treatment of microbiologically confirmed MSSA and MRSA bacteraemia. Most respondents would use an anti-staphylococcal penicillin for MSSA bacteraemia. On the other hand, three-quarters of respondents considered first-generation cephalosporins to have equivalent clinical effectiveness to anti-staphylococcal penicillins in MSSA bacteraemia without CNS infection. This is considerably higher than in a previous study among ID specialists in the USA and Canada, of whom only 32% considered nafcillin and cefazolin equivalent in the treatment of left-sided MSSA endocarditis without CNS involvement.¹⁰ This difference might be explained by the recent publication of observational studies indicating

<table><caption>**Table 2.** Preferred antibiotic treatment duration in SAB patients without implanted prosthetic material (n=536)</caption><thead><tr><th>Antibiotic treatment duration (weeks)</th><th>Arthritis n (%)</th><th>Native valve endocarditis n (%)</th><th>Osteomyelitis n (%)</th><th>Pneumonia without abscess n (%)</th><th>Septic thrombophlebitis n (%)</th><th>Vertebral osteomyelitis without abscess n (%)</th></tr></thead><tbody><tr><td>2</td><td>91 (17)</td><td>6 (1)</td><td>7 (1)</td><td>448 (84)</td><td>188 (35)</td><td>8 (1)</td></tr><tr><td>4</td><td>259 (48)</td><td>198 (37)</td><td>64 (12)</td><td>63 (12)</td><td>236 (44)</td><td>52 (10)</td></tr><tr><td>6</td><td>182 (34)</td><td>317 (59)</td><td>407 (76)</td><td>24 (4)</td><td>105 (20)</td><td>423 (79)</td></tr><tr><td>&gt;6</td><td>4 (1)</td><td>15 (3)</td><td>58 (11)</td><td>1 (0)</td><td>7 (1)</td><td>53 (10)</td></tr></tbody></table>
### Scenario 1

You are referred a 30-year old patient with methicillin-susceptible *Staphylococcus aureus* bacteremia. The patient has no relevant past medical history and no implanted prosthetic material. The infection is community-acquired and the source of infection is unknown. Time to defervescence is 36 hours. Follow-up cultures 24 hours after initiation of adequate antibiotic therapy are negative. Transesophageal echocardiography does not show signs of endocarditis and PET-CT does not show metastatic infectious sites.

### Scenario 2

You are referred a 42-year old patient with methicillin-susceptible *Staphylococcus aureus* bacteremia. The patient has an implantable cardioverter-defibrillator (ICD) in situ. Diagnostic work-up confirms infection of the ICD. The ICD is extracted on day 1 of admission. Time to defervescence is 36 hours. Follow-up cultures 24 hours after initiation of adequate antibiotic therapy are negative. Transesophageal echocardiography after extraction of the ICD does not show signs of endocarditis and PET-CT does not show metastatic infectious sites.

<caption>**Figure 2.** Scenarios describing patients with SAB.</caption>

comparable effectiveness of both agents and less antibiotic discontinuation due to adverse events in patients using cefazolin.¹¹,¹² Randomized clinical trials might provide stronger evidence about the equivalence of first-generation cephalosporins compared with anti-staphylococcal penicillins in SAB treatment.¹³,¹⁴

## Use of rifampicin

There was substantial agreement between respondents concerning the use of rifampicin for different types of prosthetic material infection. International guidelines recommend rifampicin as part of combination therapy for SAB and associated infected prosthetic material, including prosthetic valve endocarditis and prosthetic joint infections.⁶,¹⁵ The underlying evidence to support these recommendations is, however, limited since previous studies were either small or potentially suffered from confounding by indication.¹⁶⁻¹⁸ In the ARREST trial, adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in SAB.¹⁹ However, only 14 (2%) patients in this study had infected prosthetic material, limiting the generalizability of the results to this subgroup. The consensus regarding use of rifampicin, despite a lack of high-quality studies, illustrates that agreement between respondents is not always a reflection of a solid evidence base. Since rifampicin-based therapies carry a high risk of adverse drug events and drug interactions, future studies demonstrating a robust effect of rifampicin on patient outcomes are needed to justify their ubiquitous use in clinical practice.

## Oral step-down therapy

A large majority indicated they would consider oral step-down antibiotic therapy in SAB. There was relative consensus that endovascular infections, including infective endocarditis and central venous catheter infection, should not be treated with oral antibiotics. On the other hand, a majority would consider oral step-down for non-endovascular infections including arthritis,

osteomyelitis and skin-and-soft-tissue infection without abscess. This survey also highlights the fact that clinicians apply different criteria to selected patients who can be treated with oral antibiotics. Absence of CNS infection and absence of persistent bacteremia were consistent requirements for oral step-down therapy, but there was substantial disagreement on other criteria. This may originate from the fact that there is limited evidence to support the use of oral antibiotics in SAB.²⁰ Previous studies were performed in heterogeneous patient populations, included only small numbers of patients with SAB, or resulted in conflicting conclusions.²¹⁻²⁴ For example, the POET trial on partial oral treatment of endocarditis included only 47 participants with S. aureus endocarditis who received oral treatment.²⁴ We did not assess in our survey after how many days of IV therapy respondents would consider oral step-down, which might contribute to variation in respondents' answers. Currently, several studies examine the efficacy and safety of oral switch therapy in SAB, including the SABATO trial and the SNAP trial (ClinicalTrials.gov NCT05137119), and the results are eagerly awaited to inform clinical practice.²⁵

## Antibiotic treatment duration

Respondents recommended widely varying treatment durations for SAB with different foci of infection. A patient with septic arthritis and accompanying SAB would receive 4 weeks of treatment from approximately half of the respondents, 2 weeks from a fifth of respondents and 6 weeks from a third of respondents. The lack of consensus is also illustrated by respondents' answers on the factors that influence their decision to extend antibiotic therapy from 2 to 4-6 weeks. Only persistent bacteremia would prompt a majority to extend treatment. Even factors that previous studies identified as conferring a high risk for complications, such as persistent fever and delay in start of adequate antibiotic treatment, were mentioned by only a minority of respondents.²⁶ A previous survey in the USA observed similar responses regarding the factors
### Scenario 1

You are referred a 30-year old patient with methicillin-susceptible *Staphylococcus aureus* bacteremia. The patient has no relevant past medical history and no implanted prosthetic material. The infection is community-acquired and the source of infection is unknown. Time to defervescence is 36 hours. Follow-up cultures 24 hours after initiation of adequate antibiotic therapy are negative. Transesophageal echocardiography does not show signs of endocarditis and PET-CT does not show metastatic infectious sites.

### Scenario 2

You are referred a 42-year old patient with methicillin-susceptible *Staphylococcus aureus* bacteremia. The patient has an implantable cardioverter-defibrillator (ICD) in situ. Diagnostic work-up confirms infection of the ICD. The ICD is extracted on day 1 of admission. Time to defervescence is 36 hours. Follow-up cultures 24 hours after initiation of adequate antibiotic therapy are negative. Transesophageal echocardiography after extraction of the ICD does not show signs of endocarditis and PET-CT does not show metastatic infectious sites.

<caption>**Figure 2.** Scenarios describing patients with SAB.</caption>

comparable effectiveness of both agents and less antibiotic discontinuation due to adverse events in patients using cefazolin.¹¹,¹² Randomized clinical trials might provide stronger evidence about the equivalence of first-generation cephalosporins compared with anti-staphylococcal penicillins in SAB treatment.¹³,¹⁴

## Use of rifampicin

There was substantial agreement between respondents concerning the use of rifampicin for different types of prosthetic material infection. International guidelines recommend rifampicin as part of combination therapy for SAB and associated infected prosthetic material, including prosthetic valve endocarditis and prosthetic joint infections.⁶,¹⁵ The underlying evidence to support these recommendations is, however, limited since previous studies were either small or potentially suffered from confounding by indication.¹⁶⁻¹⁸ In the ARREST trial, adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in SAB.¹⁹ However, only 14 (2%) patients in this study had infected prosthetic material, limiting the generalizability of the results to this subgroup. The consensus regarding use of rifampicin, despite a lack of high-quality studies, illustrates that agreement between respondents is not always a reflection of a solid evidence base. Since rifampicin-based therapies carry a high risk of adverse drug events and drug interactions, future studies demonstrating a robust effect of rifampicin on patient outcomes are needed to justify their ubiquitous use in clinical practice.

## Oral step-down therapy

A large majority indicated they would consider oral step-down antibiotic therapy in SAB. There was relative consensus that endovascular infections, including infective endocarditis and central venous catheter infection, should not be treated with oral antibiotics. On the other hand, a majority would consider oral step-down for non-endovascular infections including arthritis,

osteomyelitis and skin-and-soft-tissue infection without abscess. This survey also highlights the fact that clinicians apply different criteria to selected patients who can be treated with oral antibiotics. Absence of CNS infection and absence of persistent bacteremia were consistent requirements for oral step-down therapy, but there was substantial disagreement on other criteria. This may originate from the fact that there is limited evidence to support the use of oral antibiotics in SAB.²⁰ Previous studies were performed in heterogeneous patient populations, included only small numbers of patients with SAB, or resulted in conflicting conclusions.²¹⁻²⁴ For example, the POET trial on partial oral treatment of endocarditis included only 47 participants with S. aureus endocarditis who received oral treatment.²⁴ We did not assess in our survey after how many days of IV therapy respondents would consider oral step-down, which might contribute to variation in respondents' answers. Currently, several studies examine the efficacy and safety of oral switch therapy in SAB, including the SABATO trial and the SNAP trial (ClinicalTrials.gov NCT05137119), and the results are eagerly awaited to inform clinical practice.²⁵

## Antibiotic treatment duration

Respondents recommended widely varying treatment durations for SAB with different foci of infection. A patient with septic arthritis and accompanying SAB would receive 4 weeks of treatment from approximately half of the respondents, 2 weeks from a fifth of respondents and 6 weeks from a third of respondents. The lack of consensus is also illustrated by respondents' answers on the factors that influence their decision to extend antibiotic therapy from 2 to 4-6 weeks. Only persistent bacteremia would prompt a majority to extend treatment. Even factors that previous studies identified as conferring a high risk for complications, such as persistent fever and delay in start of adequate antibiotic treatment, were mentioned by only a minority of respondents.²⁶ A previous survey in the USA observed similar responses regarding the factors
* Clinical effectiveness and adverse effects of first-generation cephalosporins versus anti-staphylococcal penicillins in treatment of MSSA bacteraemia.

* Evidence for use of rifampicin intreatment of prosthetic material infection.

* Safety of antibiotic oral step-down therapy for different infection foci.

* Criteria for selecting patients eligible for oral step-down therapy.

* Choice of oral antibiotic agents.

* Standard treatment duration for different infection foci.

* Criteria for selecting patients eligible for shorter and extended treatment duration.

* Yield of 18F-FDG-PET/CT and optimal strategy to incorporate it in SAB management.

<caption>**Figure 3.** Main areas of controversy in antibiotic management of SAB.</caption>

influencing extension of therapy.¹⁰ This lack of consensus may be caused by scarcity of high-quality studies, and is in line with a previous survey among ID physicians in Australia and New Zealand, which identified optimal duration of therapy as the number one research priority in SAB.¹,²⁷ Currently, randomized controlled trials are investigating whether antibiotic therapy can be safely shortened from 6 to 4 weeks in selected patients with complicated SAB (Netherlands Trial Register NL8347) and from 14 to 7 days in patients with uncomplicated SAB.²⁸

## 18F-FDG-PET/CT

Recent studies suggest that performing 18F-FDG-PET/CT might be beneficial by detecting metastatic infections, with subsequent treatment modifications.²⁹,³⁰ Half of respondents in the survey indicated they used 18F-FDG-PET/CT in SAB management, with substantial differences between countries. These local differences might be explained by differences in availability of scanners and associated costs.³¹,³² Previous surveys in the USA and Australia and New Zealand did not include questions on use of 18F-FDG-PET/CT in SAB.¹⁰,²⁷ Moreover, this survey provides insight into the way clinicians incorporate 18F-FDG-PET/CT results in decision-making in SAB management. Interestingly, we observed no major differences between respondents who used 18F-FDG-PET/CT and the group that did not, with the assumption of a negative 18F-FDG-PET/CT. These findings suggest that absence of metastatic infections on an 18F-FDG-PET/CT has at present very limited influence on the decision whether or not to extend treatment.

## Strengths and limitations

Strengths of this study are that we tested the survey format in an independent group of clinicians in the development phase, and

obtained data from a large number of respondents from different geographical regions in Europe. We acknowledge that this study has limitations. First, since participation was voluntary, selection bias may limit generalizability. Second, clinical practices were self-reported and might not adequately reflect everyday real-life practice. Furthermore, we did not assess whether respondents were primarily involved in SAB care for adults, children or both. Since clinical practice might vary per patient age group, this might have biased the results. Last, almost half of the respondents practised in France and therefore the results might disproportionally reflect clinical practice in this country. To adjust for this, we performed exploratory analyses stratified per country (Tables S1 and S2).

## Conclusions

This survey shows that considerable practice variation is present in Europe in antibiotic treatment of SAB. Clinicians have the difficult task of identifying patients who are eligible for certain targeted interventions, such as shorter, extended or oral step-down therapy. Physicians use varying criteria, as evidence from the literature is often lacking and virtually no guideline recommendations on SAB exist, which leads to clinical practice variation. This calls for methodologically sound and preferably randomized studies investigating interventions in well-defined subgroups of SAB patients. The difficulty of performing these studies is illustrated by the SABATO trial, for which enrolment started in 2013 and which was only completed in 2020 after decreasing the target sample size.²⁵ Nevertheless, such studies are much needed for guidance of clinical decision-making. The final step is to implement existing and future evidence into clinical practice, as practice variation is not only determined by lack of evidence. This survey indicates the main areas of practice
* Clinical effectiveness and adverse effects of first-generation cephalosporins versus anti-staphylococcal penicillins in treatment of MSSA bacteraemia.

* Evidence for use of rifampicin intreatment of prosthetic material infection.

* Safety of antibiotic oral step-down therapy for different infection foci.

* Criteria for selecting patients eligible for oral step-down therapy.

* Choice of oral antibiotic agents.

* Standard treatment duration for different infection foci.

* Criteria for selecting patients eligible for shorter and extended treatment duration.

* Yield of 18F-FDG-PET/CT and optimal strategy to incorporate it in SAB management.

<caption>**Figure 3.** Main areas of controversy in antibiotic management of SAB.</caption>

influencing extension of therapy.¹⁰ This lack of consensus may be caused by scarcity of high-quality studies, and is in line with a previous survey among ID physicians in Australia and New Zealand, which identified optimal duration of therapy as the number one research priority in SAB.¹,²⁷ Currently, randomized controlled trials are investigating whether antibiotic therapy can be safely shortened from 6 to 4 weeks in selected patients with complicated SAB (Netherlands Trial Register NL8347) and from 14 to 7 days in patients with uncomplicated SAB.²⁸

## 18F-FDG-PET/CT

Recent studies suggest that performing 18F-FDG-PET/CT might be beneficial by detecting metastatic infections, with subsequent treatment modifications.²⁹,³⁰ Half of respondents in the survey indicated they used 18F-FDG-PET/CT in SAB management, with substantial differences between countries. These local differences might be explained by differences in availability of scanners and associated costs.³¹,³² Previous surveys in the USA and Australia and New Zealand did not include questions on use of 18F-FDG-PET/CT in SAB.¹⁰,²⁷ Moreover, this survey provides insight into the way clinicians incorporate 18F-FDG-PET/CT results in decision-making in SAB management. Interestingly, we observed no major differences between respondents who used 18F-FDG-PET/CT and the group that did not, with the assumption of a negative 18F-FDG-PET/CT. These findings suggest that absence of metastatic infections on an 18F-FDG-PET/CT has at present very limited influence on the decision whether or not to extend treatment.

## Strengths and limitations

Strengths of this study are that we tested the survey format in an independent group of clinicians in the development phase, and

obtained data from a large number of respondents from different geographical regions in Europe. We acknowledge that this study has limitations. First, since participation was voluntary, selection bias may limit generalizability. Second, clinical practices were self-reported and might not adequately reflect everyday real-life practice. Furthermore, we did not assess whether respondents were primarily involved in SAB care for adults, children or both. Since clinical practice might vary per patient age group, this might have biased the results. Last, almost half of the respondents practised in France and therefore the results might disproportionally reflect clinical practice in this country. To adjust for this, we performed exploratory analyses stratified per country (Tables S1 and S2).

## Conclusions

This survey shows that considerable practice variation is present in Europe in antibiotic treatment of SAB. Clinicians have the difficult task of identifying patients who are eligible for certain targeted interventions, such as shorter, extended or oral step-down therapy. Physicians use varying criteria, as evidence from the literature is often lacking and virtually no guideline recommendations on SAB exist, which leads to clinical practice variation. This calls for methodologically sound and preferably randomized studies investigating interventions in well-defined subgroups of SAB patients. The difficulty of performing these studies is illustrated by the SABATO trial, for which enrolment started in 2013 and which was only completed in 2020 after decreasing the target sample size.²⁵ Nevertheless, such studies are much needed for guidance of clinical decision-making. The final step is to implement existing and future evidence into clinical practice, as practice variation is not only determined by lack of evidence. This survey indicates the main areas of practice
variation, which could be used to direct and prioritize future studies for further improvement of SAB care (Figure 3).

## Funding

This study was carried out as part of our routine work.

## Transparency declarations

Kim C. E. Sigaloff has received funding to study the optimal treatment duration for SAB from The Netherlands Organization for Health Research and Development (grant number 848018006). No other potential conflicts of interest relevant to this article exist.

## Author contributions

D. T. P. Buis conceived the study protocol together with J. M. Prins, M. G. J. de Boer, M. Ekkelenkamp, D. Kofteridis, J. Schouten, J. ten Oever and K. C. E. Sigaloff. D. T. P. Buis, L. Betica-Radic, D. Kofteridis, N. Peiffer-Smadja, J. Schouten, N. Spernovasilis and P. Tattevin performed data collection. D. T. B. Buis performed all analyses and drafted the manuscript. J. M. Prins, L. Betica-Radic, M. G. J. de Boer, M. Ekkelenkamp, D. Kofteridis, N. Peiffer-Smadja, J. Schouten, N. Spernovasilis, P. Tattevin, J. ten Oever and K. C. E. Sigaloff critically reviewed the manuscript before providing final approval.

## Supplementary data

Appendix A, Tables S1 and S2 and Figures S1 to S7 are available as Supplementary data at JAC Online.

## References

1 Tong SY, Davis JS, Eichenberger F et al. *Staphylococcus aureus* infections: epidemiology, pathophysiology, clinical manifestations, and management. *Clin Microbiol Rev* 2015; **28**: 603-61.

2 Kaasch AJ, Barlow G, Edgeworth JD et al. *Staphylococcus aureus* bloodstream infection: a pooled analysis of five prospective, observational studies. *J Infect* 2014; **68**: 242-51.

3 van der Vaart TW, Prins JM, Soetekouw R et al. Prediction rules for ruling out endocarditis in patients with *Staphylococcus aureus* bacteremia. *Clin Infect Dis* 2022; **74**: 1442-9.

4 Goto M, Schweizer ML, Vaughan-Sarrazin MS et al. Association of evidence-based care processes with mortality in staphylococcus aureus bacteremia at Veterans Health Administration hospitals, 2003-2014. *JAMA Intern Med* 2017; **177**: 1489-97.

5 Holland TL, Arnold C, Fowler VG Jr. Clinical management of *Staphylococcus aureus* bacteremia: a review. *JAMA* 2014; **312**: 1330-41.

6 Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis* 2011; **52**: e18-55.

7 Gould FK, Denning DW, Elliott TS et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. *J Antimicrob Chemother* 2012; **67**: 269-89.

8 Berbari EF, Kanj SS, Kowalski TJ et al. 2015 Infectious Diseases Society of America (IDSA) Clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. *Clin Infect Dis* 2015; **61**: e26-46.

9 Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. *Circulation* 2015; **132**: 1435-86.

10 Liu C, Strnad L, Beekmann SE et al. Clinical practice variation among adult infectious disease physicians in the management of *Staphylococcus aureus* bacteremia. *Clin Infect Dis* 2019; **69**: 530-3.

11 Lecomte R, Bourreau A, Deschanvres C et al. Comparative outcomes of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible *Staphylococcus aureus* infective endocarditis: a post hoc analysis of a prospective multicentre French cohort study. *Clin Microbiol Infect* 2021; **27**: 1015-21.

12 Lee S, Song K-H, Jung SI et al. Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible *Staphylococcus aureus* bacteremia: a prospective multicentre cohort study in Korea. *Clin Microbiol Infect* 2018; **24**: 152-8.

13 Burdet C, Loubet P, Le Moing V et al. Efficacy of cloxacillin versus cefazolin for methicillin-susceptible *Staphylococcus aureus* bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial. *BMJ Open* 2018; **8**: e023151.

14 Buis DTP. Re: 'Comparative outcomes of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post-hoc analysis multicentre French cohort study' by Lecomte et al. *Clin Microbiol Infect* 2021; **27**: 1179.

15 Habib G, Lancellotti P, Antunes MJ et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). *Eur Heart J* 2015; **36**: 3075-128.

16 Le Bot A, Lecomte R, Gazeau P et al. Is rifampin use associated with better outcome in staphylococcal prosthetic valve endocarditis? A multicenter retrospective study. *Clin Infect Dis* 2021; **72**: e249-55.

17 Zimmerli W, Widmer AF, Blatter M et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. *Foreign-Body Infection (FBI) Study Group*. *JAMA* 1998; **279**: 1537-41.

18 Perlroth J, Kuo M, Tan J et al. Adjunctive use of rifampin for the treatment of *Staphylococcus aureus* infections: a systematic review of the literature. *Arch Intern Med* 2008; **168**: 805-19.

19 Thwaites GE, Scarborough M, Szubert A et al. Adjunctive rifampicin for *Staphylococcus aureus* bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet* 2018; **391**: 668-78.

20 Dagher M, Fowler FG Jr, Wright PW et al. A narrative review of early oral stepdown therapy for the treatment of uncomplicated *Staphylococcus aureus* bacteremia: yay or nay? *Open Forum Infect Dis* 2020; **7**: ofaa151.

21 Jorgensen SCJ, Lagnf AM, Bhatia S et al. Sequential intravenous-to-oral outpatient antibiotic therapy for MRSA bacteraemia: one step closer. *J Antimicrob Chemother* 2018; **74**: 489-98.

22 Paul M, Bishara J, Yahav D et al. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by methicillin resistant *Staphylococcus aureus*: randomised controlled trial. *BMJ* 2015; **350**: h2219.

23 Willekens R, Puig-Asensio M, Ruiz-Camps I et al. Early oral switch to linezolid for low-risk patients with *Staphylococcus aureus* bloodstream infections: a propensity-matched cohort study. *Clin Infect Dis* 2018; **69**: 381-7.

24 Iversen K, Ihlemann N, Gill SU et al. Partial oral versus intravenous antibiotic treatment of endocarditis. *N Engl J Med* 2019; **380**: 415-24.
variation, which could be used to direct and prioritize future studies for further improvement of SAB care (Figure 3).

## Funding

This study was carried out as part of our routine work.

## Transparency declarations

Kim C. E. Sigaloff has received funding to study the optimal treatment duration for SAB from The Netherlands Organization for Health Research and Development (grant number 848018006). No other potential conflicts of interest relevant to this article exist.

## Author contributions

D. T. P. Buis conceived the study protocol together with J. M. Prins, M. G. J. de Boer, M. Ekkelenkamp, D. Kofteridis, J. Schouten, J. ten Oever and K. C. E. Sigaloff. D. T. P. Buis, L. Betica-Radic, D. Kofteridis, N. Peiffer-Smadja, J. Schouten, N. Spernovasilis and P. Tattevin performed data collection. D. T. B. Buis performed all analyses and drafted the manuscript. J. M. Prins, L. Betica-Radic, M. G. J. de Boer, M. Ekkelenkamp, D. Kofteridis, N. Peiffer-Smadja, J. Schouten, N. Spernovasilis, P. Tattevin, J. ten Oever and K. C. E. Sigaloff critically reviewed the manuscript before providing final approval.

## Supplementary data

Appendix A, Tables S1 and S2 and Figures S1 to S7 are available as Supplementary data at JAC Online.

## References

1 Tong SY, Davis JS, Eichenberger F et al. *Staphylococcus aureus* infections: epidemiology, pathophysiology, clinical manifestations, and management. *Clin Microbiol Rev* 2015; **28**: 603–61.

2 Kaasch AJ, Barlow G, Edgeworth JD et al. *Staphylococcus aureus* bloodstream infection: a pooled analysis of five prospective, observational studies. *J Infect* 2014; **68**: 242–51.

3 van der Vaart TW, Prins JM, Soetekouw R et al. Prediction rules for ruling out endocarditis in patients with Staphylococcus aureus bacteremia. *Clin Infect Dis* 2022; **74**: 1442–9.

4 Goto M, Schweizer ML, Vaughan-Sarrazin MS et al. Association of evidence-based care processes with mortality in staphylococcus aureus bacteremia at Veterans Health Administration hospitals, 2003-2014. *JAMA Intern Med* 2017; **177**: 1489–97.

5 Holland TL, Arnold C, Fowler VG Jr. Clinical management of *Staphylococcus aureus* bacteremia: a review. *JAMA* 2014; **312**: 1330–41.

6 Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis* 2011; **52**: e18–55.

7 Gould FK, Denning DW, Elliott TS et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. *J Antimicrob Chemother* 2012; **67**: 269–89.

8 Berbari EF, Kanj SS, Kowalski TJ et al. 2015 Infectious Diseases Society of America (IDSA) Clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. *Clin Infect Dis* 2015; **61**: e26–46.

9 Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. *Circulation* 2015; **132**: 1435–86.

10 Liu C, Strnad L, Beekmann SE et al. Clinical practice variation among adult infectious disease physicians in the management of *Staphylococcus aureus* bacteremia. *Clin Infect Dis* 2019; **69**: 530–3.

11 Lecomte R, Bourreau A, Deschanvres C et al. Comparative outcomes of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible *Staphylococcus aureus* infective endocarditis: a post hoc analysis of a prospective multicentre French cohort study. *Clin Microbiol Infect* 2021; **27**: 1015–21.

12 Lee S, Song K-H, Jung SI et al. Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible *Staphylococcus aureus* bacteremia: a prospective multicentre cohort study in Korea. *Clin Microbiol Infect* 2018; **24**: 152–8.

13 Burdet C, Loubet P, Le Moing V et al. Efficacy of cloxacillin versus cefazolin for methicillin-susceptible *Staphylococcus aureus* bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial. *BMJ Open* 2018; **8**: e023151.

14 Buis DTP. Re: 'Comparative outcomes of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post-hoc analysis multicentre French cohort study' by Lecomte et al. *Clin Microbiol Infect* 2021; **27**: 1179.

15 Habib G, Lancellotti P, Antunes MJ et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). *Eur Heart J* 2015; **36**: 3075–128.

16 Le Bot A, Lecomte R, Gazeau P et al. Is rifampin use associated with better outcome in staphylococcal prosthetic valve endocarditis? A multicenter retrospective study. *Clin Infect Dis* 2021; **72**: e249–55.

17 Zimmerli W, Widmer AF, Blatter M et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. *Foreign-Body Infection (FBI) Study Group*. *JAMA* 1998; **279**: 1537–41.

18 Perlroth J, Kuo M, Tan J et al. Adjunctive use of rifampin for the treatment of *Staphylococcus aureus* infections: a systematic review of the literature. *Arch Intern Med* 2008; **168**: 805–19.

19 Thwaites GE, Scarborough M, Szubert A et al. Adjunctive rifampicin for *Staphylococcus aureus* bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. *Lancet* 2018; **391**: 668–78.

20 Dagher M, Fowler FG Jr, Wright PW et al. A narrative review of early oral stepdown therapy for the treatment of uncomplicated *Staphylococcus aureus* bacteremia: yay or nay? *Open Forum Infect Dis* 2020; **7**: ofaa151.

21 Jorgensen SCJ, Lagnf AM, Bhatia S et al. Sequential intravenous-to-oral outpatient antibiotic therapy for MRSA bacteraemia: one step closer. *J Antimicrob Chemother* 2018; **74**: 489–98.

22 Paul M, Bishara J, Yahav D et al. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by methicillin resistant *Staphylococcus aureus*: randomised controlled trial. *BMJ* 2015; **350**: h2219.

23 Willekens R, Puig-Asensio M, Ruiz-Camps I et al. Early oral switch to linezolid for low-risk patients with *Staphylococcus aureus* bloodstream infections: a propensity-matched cohort study. *Clin Infect Dis* 2018; **69**: 381–7.

24 Iversen K, Ihlemann N, Gill SU et al. Partial oral versus intravenous antibiotic treatment of endocarditis. *N Engl J Med* 2019; **380**: 415–24.
**25** Kaasch AJ, Rommerskirchen A, Hellmich M *et al*. Protocol update for the SABATO trial: a randomized controlled trial to assess early oral switch therapy in low-risk *Staphylococcus aureus* bloodstream infection. *Trials* 2020; **21**: 175.

**26** Fowler VG Jr, Olsen MK, Corey GR *et al*. Clinical identifiers of complicated *Staphylococcus aureus* bacteremia. *Arch Intern Med* 2003; **163**: 2066-72.

**27** Tong SYC, Campbell A, Bowen AC *et al*. A survey of infectious diseases and microbiology clinicians in Australia and New Zealand about the management of *Staphylococcus aureus* bacteremia. *Clin Infect Dis* 2019; **69**: 1835-6.

**28** Thorlacius-Ussing L, Andersen CØ, Frimodt-Møller N *et al*. Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated *Staphylococcus aureus* bacteremia (SAB7): study protocol for a randomized controlled trial. *Trials* 2019; **20**: 250.

**29** Ghanem-Zoubi N, Kagna O, Abu-Elhija J *et al*. Integration of FDG-PET/CT in the diagnostic workup for *Staphylococcus aureus* bacteremia: a prospective interventional matched-cohort study. *Clin Infect Dis* 2021; **73**: e3859-66.

**30** Berrevoets MAH, Kouijzer IJE, Aarntzen EHJG *et al*. (18)F-FDG PET/CT optimizes treatment in *Staphylococcus aureus* bacteremia and is associated with reduced mortality. *J Nucl Med* 2017; **58**: 1504-10.

**31** Li Y, Wang Q, Wang X *et al*. Expert consensus on clinical application of FDG PET/CT in infection and inflammation. *Ann Nucl Med* 2020; **34**: 369-76.

**32** Douglas AP, Thursky KA, Worth LJ *et al*. Access, knowledge and experience with fluorodeoxyglucose positron emission tomography/computed tomography in infection management: a survey of Australia and New Zealand infectious diseases physicians and microbiologists. *Intern Med J* 2019; **49**: 615-21.
25 Kaasch AJ, Rommerskirchen A, Hellmich M et al. Protocol update for the SABATO trial: a randomized controlled trial to assess early oral switch therapy in low-risk *Staphylococcus aureus* bloodstream infection. *Trials* 2020; **21**: 175.

26 Fowler VG Jr, Olsen MK, Corey GR et al. Clinical identifiers of complicated *Staphylococcus aureus* bacteremia. *Arch Intern Med* 2003; **163**: 2066-72.

27 Tong SYC, Campbell A, Bowen AC et al. A survey of infectious diseases and microbiology clinicians in Australia and New Zealand about the management of *Staphylococcus aureus* bacteremia. *Clin Infect Dis* 2019; **69**: 1835-6.

28 Thorlacius-Ussing L, Andersen CØ, Frimodt-Møller N et al. Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated *Staphylococcus aureus* bacteremia (SAB7): study protocol for a randomized controlled trial. *Trials* 2019; **20**: 250.

29 Ghanem-Zoubi N, Kagna O, Abu-Elhija J et al. Integration of FDG-PET/CT in the diagnostic workup for *Staphylococcus aureus* bacteremia: a prospective interventional matched-cohort study. *Clin Infect Dis* 2021; **73**: e3859-66.

30 Berrevoets MAH, Kouijzer IJE, Aarntzen EHJG et al. (18)F-FDG PET/CT optimizes treatment in *Staphylococcus aureus* bacteremia and is associated with reduced mortality. *J Nucl Med* 2017; **58**: 1504-10.

31 Li Y, Wang Q, Wang X et al. Expert consensus on clinical application of FDG PET/CT in infection and inflammation. *Ann Nucl Med* 2020; **34**: 369-76.

32 Douglas AP, Thursky KA, Worth LJ et al. Access, knowledge and experience with fluorodeoxyglucose positron emission tomography/computed tomography in infection management: a survey of Australia and New Zealand infectious diseases physicians and microbiologists. *Intern Med J* 2019; **49**: 615-21.